Loading...
•
Dec 31, 2025
Myriad Genetics Q4 2025 Earnings Report
Myriad Genetics reported flat fourth quarter 2025 revenue year-over-year with improved adjusted profitability and continued volume growth in key segments.
Key Takeaways
Myriad Genetics delivered fourth quarter 2025 revenue of 209800000 with stable year-over-year performance, a GAAP net loss of 7900000, and adjusted EPS of 0.04. Test volumes increased 2% year-over-year, driven by growth in hereditary cancer and mental health testing, while gross margin remained at 70.0%.
Fourth quarter revenue was 209800000, consistent year-over-year.
GAAP net loss narrowed to 7900000 with adjusted EPS of 0.04.
Gross margin was 70.0%, in line with the prior quarter.
Test volumes grew 2% year-over-year, led by hereditary cancer and mental health.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company reiterated full-year 2026 revenue guidance of 860000000 to 880000000 and expects adjusted gross margin between 68% and 69%, with adjusted EBITDA of 37000000 to 49000000.
Positive Outlook
- Full-year 2026 revenue guidance reaffirmed at 860000000 to 880000000.
- Expected year-over-year revenue growth in Q1 2026 of 2% to 4%.
- Adjusted gross margin projected between 68% and 69%.
- Adjusted EBITDA guidance of 37000000 to 49000000.
- Revenue expected to be higher in the second half of 2026.
Challenges Ahead
- Q1 2026 adjusted EBITDA expected to be near breakeven.
- Unfavorable year-over-year comparison for prenatal testing in Q1 2026.
- Gross margin expected to fluctuate quarter to quarter.
- Guidance excludes GAAP reconciliation due to forecasting uncertainty.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...